Stay updated on CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page.

Latest updates to the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page
- CheckyesterdayChange DetectedThe page now displays Revision: v3.5.4, updating the revision label from the previous v3.5.3. This reflects a new entry in the page's revision history.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe interface revision tag was updated from v3.5.2 to v3.5.3. This reflects a minor platform update with no changes to the study details presented on the page.SummaryDifference0.1%

- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedRevision: v3.5.2 now appears on the page, replacing the previous Revision: v3.5.0.SummaryDifference0.1%

- Check59 days agoChange DetectedRevision history updated: added Revision v3.5.0 and removed Revision v3.4.2.SummaryDifference0.1%

- Check94 days agoChange DetectedA new page revision label 'Revision: v3.4.2' is added, and an operating-status notice about government funding as well as the older 'Revision: v3.4.1' label are removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check102 days agoChange DetectedAdded a system-wide notice about government funding status and NIH operations. Updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.5%

Stay in the know with updates to CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page.